Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin

descriptionPublicationkeyboard_double_arrow_right Article 01 Oct 1997 English Publisher:Oxford University Press (OUP)Journal:Clinical Infectious Diseases, volume 25, pages 911-914 (issn: 1058-4838, eissn: 1537-6591,

Copyright policy )

Authors: A M, Kesson; J K, Ferguson; W D, Rawlinson; A L, Cunningham;

doi: 10.1086/515534

pmid: 9356807

Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin

- Summary
- Subjects
- Metrics

Abstract

A 67-year-old man with metastatic melanoma and chronic lymphocytic leukemia was inadvertently given a vaccinia melanoma oncolysate vaccination. He developed progressive vaccinia at the site of inoculation. The lesion started to heal only when he was treated with ribavirin. Vaccinia immune globulin was administered and appeared to help control the initial lesion and limit the development of satellite lesions.

Related Organizations

University of Newcastle Australia
Australia
Westmead Hospital
Australia

Keywords

Male, Skin Neoplasms, Vaccination, Antibodies, Viral, Antiviral Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Ribavirin, Vaccinia, Humans, Melanoma, Aged

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	56
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average